阅读说明：本技术 辛酸钠在制备改善心肺复苏效果以及心肺复苏后多器官功能障碍的药物中的应用 (Application of sodium caprylate in preparation of medicine for improving cardio-pulmonary resuscitation effect and multi-organ dysfunction after cardio-pulmonary resuscitation ) 是由 张茂 徐杰丰 于 2021-10-22 设计创作，主要内容包括：本发明提供了一种辛酸钠在制备改善心肺复苏效果以及心肺复苏后多器官功能障碍的药物中的应用,涉及药物制剂技术领域。上述用于改善心肺复苏效果及复苏后多器官功能障碍的药物包括施用药学有效剂量的辛酸钠,该药物通过施用药学有效剂量的辛酸钠,所述辛酸钠用于在心脏骤停复苏导致的系统性缺血再灌注损伤过程中促进脂肪酸氧化供能,进而可以有效改善心肺复苏效果及复苏后多器官功能障碍。(The invention provides an application of sodium caprylate in preparing a medicine for improving cardio-pulmonary resuscitation effect and multi-organ dysfunction after cardio-pulmonary resuscitation, and relates to the technical field of pharmaceutical preparations. The medicine for improving the cardio-pulmonary resuscitation effect and the multiple organ dysfunction after resuscitation comprises the sodium caprylate with the pharmaceutically effective dose, and the sodium caprylate is used for promoting fatty acid oxidation energy supply in the process of systemic ischemia reperfusion injury caused by cardiac arrest resuscitation so as to effectively improve the cardio-pulmonary resuscitation effect and the multiple organ dysfunction after resuscitation.)

1. Use of sodium caprylate in the manufacture of a medicament for improving cardiopulmonary resuscitation.

2. The use of claim 1, wherein said use is the administration of a pharmaceutically effective dose of sodium caprylate.

3. The use according to claim 2, wherein the pharmaceutically effective dose of sodium caprylate is 14.2-28.5 mg/kg, preferably 28.5 mg/kg.

4. The use of claim 1, wherein the effect of sodium caprylate on improving cardiopulmonary resuscitation is to effectively power the body in a stressed state of the body.

5. The use of claim 1, wherein the medicament is an injection.

6. Use of sodium caprylate for the manufacture of a medicament for improving multiple organ dysfunction after cardiopulmonary resuscitation.

7. The use of claim 6, wherein said use is the administration of a pharmaceutically effective dose of sodium caprylate.

8. The use according to claim 6, wherein the pharmaceutically effective dose of sodium caprylate is 14.2-28.5 mg/kg, preferably 28.5 mg/kg.

9. The use of claim 6, wherein the sodium caprylate is used to promote fatty acid oxidative energizing during systemic ischemia reperfusion injury resulting from cardiac arrest resuscitation.

10. The use of claim 6, wherein the multiple organ dysfunction comprises impaired cardiac function, impaired brain function, and impaired renal-intestinal function;

preferably, the medicament is an injection.

Technical Field

The invention relates to the technical field of pharmaceutical preparations, in particular to application of sodium caprylate in preparing a medicament for improving cardio-pulmonary resuscitation effect and multi-organ dysfunction after cardio-pulmonary resuscitation.

Background

Sudden cardiac arrest events are a major public health problem with high incidence and low survival rates worldwide. The survival rate of the patients discharged from hospital is only about 10 percent, and a large number of surviving patients have serious neurological dysfunction, which becomes an important reason for human death and poor survival prognosis.

Research shows that after a cardiac arrest event occurs, the energy supply of an organism is rapidly reduced to be interrupted, and then various pathological damage ways such as oxidative stress, inflammatory reaction, mitochondrial dysfunction and the like are started, so that cells are killed in various forms such as apoptosis, necrosis, scorching and the like, and finally, multiple organ dysfunction and even death of the organism are caused. Therefore, in the cardiopulmonary resuscitation treatment process after the cardiac arrest event, effective energy substances are timely supplemented in an early stage, the occurrence and development processes of the pathological damage ways can be stopped, and further the damage degree of important organs is reduced and the survival prognosis outcome of a patient is improved.

Currently, the most clinically common and readily available energy supplement substance is glucose. However, the body, after experiencing a severe stroke from a cardiac arrest event, often develops states of insulin resistance, impaired glucose utilization, and further, stress hyperglycemia.

Therefore, it is necessary and urgent to search for an effective energy-supplying substance that can replace glucose under stress conditions, and thus effectively improve the cardio-pulmonary resuscitation effect and the multi-organ dysfunction after resuscitation.

In view of the above, the present invention is particularly proposed.

Disclosure of Invention

The invention aims to provide a medicine for improving cardio-pulmonary resuscitation effect and multi-organ dysfunction after resuscitation.

In order to achieve the above purpose of the present invention, the following technical solutions are adopted:

the invention provides application of sodium caprylate in preparing a medicine for improving cardio-pulmonary resuscitation effect.

Further, the use is the administration of a pharmaceutically effective dose of sodium caprylate.

Furthermore, the pharmaceutically effective dose of the sodium caprylate is 14.2-28.5 mg/kg, preferably 28.5 mg/kg.

Further, the effect of sodium caprylate on improving cardiopulmonary resuscitation is to effectively supply energy to the body under the stress state of the body.

Further, the medicament is an injection.

The invention provides application of sodium caprylate in preparing a medicine for improving multiple organ dysfunction after cardiopulmonary resuscitation.

Further, the use is the administration of a pharmaceutically effective dose of sodium caprylate.

Further, the pharmaceutically effective dose of the sodium caprylate is 14.2-28.5 mg/kg, preferably 28.5 mg/kg.

Further, the sodium caprylate is used to promote fatty acid oxidative energizing during systemic ischemia reperfusion injury resulting from cardiac arrest resuscitation.

Further, the multiple organ dysfunction includes impairment of cardiac function, impairment of brain function, and impairment of renal bowel function;

preferably, the medicament is an injection.

Compared with the prior art, the invention has the beneficial effects that:

the application of the sodium caprylate provided by the invention in preparing the medicine for improving the effect of cardiopulmonary resuscitation comprises the step of administering the sodium caprylate with a pharmaceutically effective dose, wherein the method for improving the effect of cardiopulmonary resuscitation by the sodium caprylate is to effectively supply energy to a human body in a stress state of the human body.

The invention provides an application of sodium caprylate in preparing a medicament for improving multiple organ dysfunction after cardiopulmonary resuscitation, which comprises the step of administering a pharmaceutically effective dose of sodium caprylate, wherein the sodium caprylate is used for promoting fatty acid oxidative energy supply in a systemic ischemia-reperfusion injury process caused by cardiac arrest resuscitation.

Drawings

In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.

FIG. 1 is a graph showing the effect of sodium caprylate on the level of perfusion of cardiac and cerebral organs during cardiopulmonary resuscitation provided in example 3 of the present invention;

FIG. 2 is a graph showing the changes in cardiac function and damage markers of various groups of animals according to example 4 of the present invention;

FIG. 3 is a diagram of the changes in brain function and injury markers for various groups of animals according to example 4 of the present invention;

FIG. 4 is a graph showing the changes in the markers of renal bowel injury in various groups of animals according to example 4 of the present invention;

FIG. 5 is a graph showing the analysis of the degree of apoptosis of the cardiac, cerebral, renal and intestinal histiocytes after the recovery of each group of animals provided in example 5 of the present invention.

Detailed Description

The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments, and it should be understood that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

According to one aspect of the invention, the use of sodium caprylate for the manufacture of a medicament for improving cardiopulmonary resuscitation.

The application of the sodium caprylate provided by the invention in preparing the medicine for improving the effect of cardiopulmonary resuscitation comprises the step of administering the sodium caprylate with a pharmaceutically effective dose, wherein the method for improving the effect of cardiopulmonary resuscitation by the sodium caprylate is to effectively supply energy to a human body in a stress state of the human body.

It should be noted that the existing research shows that fatty acid is an effective energy supplying substance for replacing glucose in the stress state of the body, and the representative substance of the fatty acid sodium caprylate is proved to be good research. Initially, sodium caprylate was found to be an important energy substrate for the fatty acid oxidation energy supply pathway and to be an energy source for important organs such as heart, liver, skeletal muscle, etc. Recently, studies have reported that sodium caprylate can improve the functional state of ischemia reperfusion-damaged myocardium by enhancing fatty acid oxidative energy supply pathway, and the protective mechanism is related to inhibition of mitochondrial oxidative stress injury. However, it is not clear whether sodium caprylate can improve cardiopulmonary resuscitation effect by promoting fatty acid oxidative energy supply and multi-organ dysfunction after resuscitation during systemic ischemia-reperfusion injury caused by cardiac arrest resuscitation. Therefore, the research confirms the application effect of the sodium caprylate in the cardiopulmonary resuscitation treatment after cardiac arrest and the multi-organ protection after resuscitation, and the product research and clinical transformation of the medicine are carried out on the basis, so that a new important medical means is provided for the clinical cardiopulmonary resuscitation treatment, and the medicine has good research significance and application prospect.

Preferably, the improved cardiopulmonary resuscitation effect consists in increasing survival of the individual.

In a preferred embodiment of the present invention, the pharmaceutically effective dose of sodium caprylate is 14.2-28.5 mg/kg, preferably 28.5 mg/kg.

In a preferred embodiment of the invention, the effect of sodium caprylate on improving cardiopulmonary resuscitation is to effectively power the body in a stressed state of the body.

In a preferred embodiment of the present invention, the drug is an injection.

According to one aspect of the invention, the use of sodium caprylate for the preparation of a medicament for improving multi-organ dysfunction after cardiopulmonary resuscitation.

The invention provides an application of sodium caprylate in preparing a medicament for improving multiple organ dysfunction after cardiopulmonary resuscitation, which comprises the step of administering a pharmaceutically effective dose of sodium caprylate, wherein the sodium caprylate is used for promoting fatty acid oxidative energy supply in a systemic ischemia-reperfusion injury process caused by cardiac arrest resuscitation.

Preferably, the medicament comprises sodium caprylate and a pharmaceutically acceptable carrier.

In a preferred embodiment of the present invention, the pharmaceutically effective dose of sodium caprylate is 14.2-28.5 mg/kg, preferably 28.5 mg/kg.

In a preferred embodiment of the invention, the sodium caprylate is used to promote fatty acid oxidative energizing during systemic ischemia reperfusion injury resulting from cardiac arrest resuscitation.

In a preferred embodiment of the invention, the multiple organ dysfunction includes impaired cardiac function, impaired brain function, and impaired renal bowel function;

in a preferred embodiment of the present invention, the drug is an injection.

The technical solution of the present invention will be further described with reference to the following examples.

Example 1 animal preparation

1. All animals began fasting without water deprivation at 12h prior to the experiment.

2. The experimental animals are firstly anesthetized by intramuscular injection of 0.4-0.5mg/kg of midazolam, connected with an electrocardiogram monitor, then are subjected to general anesthesia by ear edge intravenous injection of 2mg/kg of propofol, and then are pumped into a vein of 4mg/kg/h to maintain the anesthesia state.

3. Rapid intubation of trachea, partial pressure of end-tidal carbon dioxide (ETCO)₂) Monitoring and mechanically ventilating with Intermittent Positive Pressure Ventilation (IPPV) mode, oxygen concentration of 21%, tidal volume of 10ml/kg, and positive end expiratory pressure of 0mmHg, and maintaining ETCO by regulating respiratory frequency₂In the normal physiological range of 35-40 mmHg.

4. The right femoral artery and vein are exposed by operation, and a Swan-Ganz catheter is respectively placed into the thoracic aorta and the right atrium, wherein the Swan-Ganz catheter is used for monitoring the aortic blood pressure and collecting arterial blood samples, the main catheter cavity of the Swan-Ganz catheter is used for monitoring the right atrial pressure and temperature and collecting venous blood samples, the side catheter cavity is used for infusing therapeutic drugs, and the level of Coronary Perfusion Pressure (CPP) is calculated according to the difference value of the aortic blood pressure and the right atrial pressure.

5. The right external jugular vein is exposed by operation, and an induction electrode for ventricular fibrillation is placed into the right ventricle for later induction of ventricular fibrillation.

6. The right internal jugular vein and the left femoral artery are exposed by operation, a central venous catheter and a thermodilution arterial catheter are respectively arranged, and the central venous catheter and the thermodilution arterial catheter are connected with a pulse indication continuous heart blood discharge (PicCO) monitor and used for monitoring the change of cardiac function indexes such as Stroke Volume (SV) and total cardiac ejection fraction (GEF).

7. And (3) exposing the right carotid artery through operation, peeling off a surface fascia, sleeving a carotid blood flow sensor, connecting a blood flow velocity ultrasonic recorder, and monitoring the change of Carotid Blood Flow (CBF) in real time.

8. Shaving animal forehead hair, exposing forehead skin, cleaning with ethanol, attaching cerebral oxygen monitoring probe, connecting with cerebral oxygen monitor, and monitoring cerebral oxygen saturation (rSO) in real time₂) A change in (c).

9. The temperature of the animal is maintained at normal temperature of about 38 ℃ by using the temperature control blanket.

Example 2 modeling

1. Setting model conditions: sudden cardiac arrest for 8min + cardiopulmonary resuscitation for 8 min.

2. Cardiac arrest method: ventricular fibrillation was induced by right ventricular electrode discharge, observed for 8min without intervention.

3. The cardiopulmonary resuscitation method comprises the following steps:

1) continuous artificial chest compressions;

2) mechanical ventilation is carried out by using a respirator (parameters are IPPV mode, oxygen concentration is 100%, tidal volume is 7ml/kg, respiratory frequency is 10 times/min, and positive end expiratory pressure is 0 mmHg);

3) adrenalin: when the cardiopulmonary resuscitation is performed for 2min, the dosage is 20 mug/kg, and the operation is repeated for 1 time every 4 min;

4) defibrillation: performing 150J electrical defibrillation for 1 time when the heart and lung are resuscitated for 8 min;

5) if the spontaneous circulation is not recovered, the cardio-pulmonary resuscitation is immediately restarted for 2min, and then the defibrillation is carried out for 1 time, and the circulation is repeated for less than or equal to 5 times until the resuscitation is successful or failure is declared.

4. Monitoring for 4h after resuscitation:

1) restarting mechanical ventilation (parameters are IPPV mode, oxygen concentration is 21%, tidal volume is 10ml/kg, positive end expiratory pressure is 3mmHg, and respiratory frequency is recovered to the pre-molding state);

2) continuing anesthesia monitoring;

3) normal body temperature of 38 ℃ was maintained.

5. And observing the pigsty for 20 h.

Example 3 animal testing

(I) experimental grouping:

domestic healthy male white pigs with 24 heads and weight of about 35kg are randomly divided into 3 groups: sham group (n ═ 6), CPR group (n ═ 10), CPR + SO group (n ═ 8).

(II) intervention measures:

1) sham group: the same group of patients is administered with the same amount of the solvent intravenously without establishing a cardiac arrest resuscitation model;

2) CPR group: establishing a cardiac arrest resuscitation model, and simultaneously, intravenously administering the same amount of menstruum to other groups at the same time of starting CPR;

3) CPR + SO group: a cardiac arrest resuscitation model was set up and 28.5mg/kg of sodium caprylate dissolved in an equal amount of vehicle was administered intravenously at the same time as CPR was initiated.

Note: sham, Sham; CPR, cardiopulmonary resuscitation; SO, sodium caprylate.

(III) observation indexes:

1. during the experiment monitoring period, the heart rate, the blood pressure and the ETCO are dynamically monitored in the whole course₂、CBF、rSO₂And the change of physiological indexes such as body temperature and the like, and the survival condition of the animals at 4h and 24h is recorded.

2. Continuous dynamic monitoring of CPP, ETCO during cardiopulmonary resuscitation₂、CBF、rSO₂And recording the cardio-pulmonary resuscitation time, the defibrillation times, the adrenaline dosage, the spontaneous circulation recovery ratio and the like of each group of animals.

3. Before modeling and at 1h, 2h and 4h after resuscitation, a PicCO monitor is used for periodically detecting the change of cardiac function indexes such as Stroke Volume (SV), whole heart ejection fraction (GEF) and the like.

4. Before modeling and at 1h, 2h, 4h and 24h after recovery, collecting venous blood samples, centrifuging to obtain blood plasma, freezing and storing in a-80 ℃ deep low-temperature refrigerator, and detecting the serum levels of cardiac muscle injury marker cardiac troponin I (cTnI), brain injury marker neuron-specific enolase (NSE) and S100B protein (S100B), kidney and intestine injury marker creatinine (Cr) and Intestinal Fatty Acid Binding Protein (iFABP) by an enzyme-linked immunosorbent assay at selected time.

5. And (3) performing neurological function evaluation by using Neurological Deficit Scoring (NDS) 24h after resuscitation, then performing euthanasia on animals, rapidly obtaining tissues of parts such as the apical part of the left ventricle, the frontal cortex of the brain, the upper pole of the right kidney, the tail end of the ileum and the like, performing fixation, embedding, slicing and other treatment, and detecting the apoptosis degree of organ tissues such as the heart, the brain, the kidney, the intestine and the like by using an in-situ terminal labeling method (TUNEL).

(IV) specific test results:

1. basic conditions for each group of animals:

baseline data of three groups of animals, e.g. weight, heart rate, mean arterial pressure, ETCO₂、CBF、rSO₂Physiological indexes such as body temperature and the like, and comparative differences among groups have no statistical significance (P in all)>0.05). See table 1.

TABLE 1 basic conditions of the animals of the groups

Note: ETCO₂End-tidal carbon dioxide partial pressure; CBF, carotid blood flow; rSO₂The brain oxygen saturation; sham, Sham; CPR, cardiopulmonary resuscitation; SO, sodium caprylate.

2. Cardiopulmonary resuscitation outcome for each group of animals:

the CPR and CPR + SO groups undergo a cardiac arrest resuscitation process. However, during cardiopulmonary resuscitation, the CPR + SO group CPP, ETCO₂、CBF、rSO₂The isocardiac cerebral perfusion index is obviously higher than that of the CPR group at almost all time points, and the comparative difference between the groups has statistical significance (mean P)<0.05). See in particular fig. 1.

FIG. 1 is a graph showing the effect of sodium caprylate on the level of perfusion of cardiac and cerebral organs during cardiopulmonary resuscitation. In fig. 1, a is a diagram of the level change of coronary perfusion pressure; in FIG. 1, B is a graph showing the change in the level of carotid blood flow; c in FIG. 1 is a graph showing the change in the level of the end-tidal carbon dioxide partial pressure; in fig. 1, D is a graph showing the change in the level of brain oxygen saturation.

In fig. 1, CPP is coronary perfusion pressure; CBF is carotid blood flow; ETCO₂Is the end-tidal carbon dioxide partial pressure; rSO₂Is the brain oxygen saturation; CPR is cardiopulmonary resuscitation; SO is octanoic acidSodium. In comparison with the CPR group,^#P<0.05。

specifically, compared with the CPR group, the CPR + SO group has the advantages of shortened cardiopulmonary resuscitation time, reduced defibrillation frequency, reduced epinephrine dosage, increased spontaneous circulation recovery rate, and survival rate of 4h and 24h, and has statistical significance for comparison and difference among groups (P < 0.05). See table 2.

Table 2. cardiopulmonary resuscitation outcome for each group of animals:

note: CPR, cardiopulmonary resuscitation; SO, sodium caprylate. In comparison with the CPR group,^#P<0.05。

example 4 groups of animals injury marker analysis

1. Changes in cardiac function and injury markers for each group of animals:

before modeling, the three groups of cardiac function indexes SV and GEF values, the myocardial injury marker cTnI serum levels and the comparative differences among the groups have no statistical significance (P is more than 0.05). After resuscitation, the SV and GEF values were clearly lower in the CPR group and the CPR + SO group than in the Sham group, while the cTnI serum level was significantly higher than in the Sham group, and the differences between the groups were statistically significant (mean P < 0.05). However, both SV and GEF values were significantly higher after 1h of resuscitation in the CPR + SO group, and cTnI serum levels were significantly lower after 4h of resuscitation in the CPR group compared to the CPR group, with statistical differences between groups (mean P < 0.05). See fig. 2.

FIG. 2 is a graph showing the change of cardiac function and injury markers in each group of animals. Fig. 2 a is a graph of the change per output; in FIG. 2, B is a graph showing the variation of the total cardiac ejection fraction; in FIG. 2, C is a graph showing the change in cardiac troponin;

in fig. 2, SV is stroke volume; GEF is total heart ejection fraction; cTnI is cardiac troponin; BL is a baseline value; sham is a Sham operation; CPR is cardiopulmonary resuscitation; SO is sodium caprylate; in contrast to the Sham group,^*P<0.05，^**P<0.01; in contrast to the CPR group,^#P<0.05，^##P<0.01。

2. changes in brain function and injury markers for each group of animals:

before modeling, the serum levels of three groups of brain injury markers NSE and S100B have no statistical significance when compared with each other (P > 0.05). After resuscitation, the serum NSE and S100B levels of the CPR group after 1h of resuscitation are obviously higher than those of the Sham group, the serum NSE level of the CPR + SO group after 4h of resuscitation and the serum S100B level of the CPR + SO group after 2h of resuscitation are obviously higher than those of the Sham group, and the comparison difference between the groups has statistical significance (P < 0.05). However, the NSE serum levels were significantly reduced at 4h and 24h after resuscitation in the CPR + SO group and at 1h, 2h and 24h after resuscitation in S100B in the CPR + SO group compared to the CPR group, with statistical significance for the differences between the groups (mean P < 0.05). In addition, the NDS score at 24h after resuscitation was significantly higher in the CPR and CPR + SO groups than in the Sham group, while the NDS score was significantly lower in the CPR + SO group than in the CPR group, all the differences between the groups were statistically significant (all P < 0.05). See fig. 3.

FIG. 3 is a graph showing changes in brain function and injury markers for each group of animals. Wherein A in FIG. 3 is a change diagram of neuron-specific enolase; b in FIG. 3 is a change pattern of the S100B protein; in FIG. 3, C is a neurological deficit score chart;

in fig. 3, NSE is neuron-specific enolase; S100B is S100B protein; NDS is neurological deficit score; BL is a baseline value; sham is a Sham operation; CPR is cardiopulmonary resuscitation; SO is sodium caprylate; in contrast to the Sham group,^*P<0.05; in contrast to the CPR group,^#P<0.05。

3. change in Kidney gut injury marker in Each group of animals

Before modeling, the serum levels of the three renal and intestinal injury markers Cr and iFABP have no statistical significance in comparison and difference among groups (P is more than 0.05). After resuscitation, the levels of Cr and iFABP in the serum of the CPR group and the CPR + SO group are obviously higher than those of the Sham group, and the comparison difference between the groups has statistical significance (the mean P is less than 0.05). However, compared to the CPR group, the serum levels of Cr in the CPR + SO group were significantly reduced at 2h and 24h after resuscitation, and iFABP at 24h after resuscitation, and the differences between groups were statistically significant (mean P < 0.05). See fig. 4.

FIG. 4 is a graph showing the change of the markers of renal intestine injury in each group of animals; in fig. 4, A is a graph of creatinine change; in FIG. 4B is a change chart of the intestinal fatty acid binding protein; in fig. 4, Cr is creatinine; iFABP is an intestinal fatty acid binding protein; BL is a baseline value; sham is a Sham operation; CPR is cardiopulmonary resuscitation; SO is sodium caprylate; in contrast to the Sham group,^*P<0.05; in contrast to the CPR group,^#P<0.05。

example 5 analysis of the degree of apoptosis of the cells of the tissues of the heart, brain, kidney and intestine of various groups of animals after recovery

At 24h after resuscitation, all groups of surviving animals are euthanized, organ tissues such as heart, brain, kidney, intestine and the like are obtained for pathological analysis, and the results show that compared with the Sham group, the proportion of apoptotic cells of the organ tissues of the CPR group and the CPR + SO group is obviously increased, and the comparison difference between the groups has statistical significance (P is less than 0.05). However, compared with the CPR group, the degree of apoptosis of each organ tissue cell in the CPR + SO group is obviously reduced, and the comparison difference between the groups has statistical significance (mean P < 0.05). See fig. 5.

FIG. 5 is the analysis chart of the apoptosis degree of the cardio-cerebral-renal-intestinal histiocyte after the recovery of each group of animals. In fig. 5, Heart is Heart; cortex is the Cortex; hippocampus is Hippocampus; kidney is Kidney; bowel is intestine; TUNEL is a former terminal labeling method; sham is a Sham operation; CPR is cardiopulmonary resuscitation; SO is sodium caprylate. In comparison with the Sham group,^*P<0.05; in comparison with the CPR group,^#P<0.05。

in summary, the medicine for improving cardiopulmonary resuscitation effect and post-resuscitation multiple organ dysfunction comprises sodium caprylate and a pharmaceutically acceptable carrier, and the medicine is prepared by administering a pharmaceutically effective dose of sodium caprylate, wherein the sodium caprylate is used for promoting fatty acid oxidation energy supply in a process of systemic ischemia reperfusion injury caused by cardiac arrest resuscitation, so that the cardiopulmonary resuscitation effect and post-resuscitation multiple organ dysfunction can be effectively improved.

Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.